• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

DNAPrint Genomics Engages Harvard Physician and Scientist As Consultant to Company

Posted on: Tuesday, 8 August 2006, 12:01 CDT

DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Dr. Arthur Sytkowski, the Director of the Laboratory for Cell and Molecular Biology at Beth Israel Deaconess Medical Center (BIDMC), an affiliate of Harvard Medical School, will continue as a consultant for the Company on scientific, medical, regulatory and patent issues.

"We are pleased that Dr. Sytkowski will remain such an integral part of our Company," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "As one of the foremost scientists in the field of therapeutic protein research and particularly Erythropoietin, Dr. Sytkowski will bring to bear his considerable expertise on the development and the marketing of PT-401, our lead pharmaceutical product being developed for the treatment of anemia. We look forward to working with him on this project and any future endeavors."

Dr. Sytkowski is a physician and scientist with more than 25 years of clinical and research experience in the fields of oncology, hematology, cell and molecular biology, and protein biochemistry. He is an Associate Professor in the Department of Medicine at the Harvard Medical School and a member of the Division of Hematology and Oncology at BIDMC. He has authored a book on Erythropoietin entitled "Erythropoietin: Blood, Brain and Beyond" and has authored many scientific papers and several milestone patents covering Erythropoietin. Furthermore, he has served as an expert witness and advisor to leading pharmaceutical companies selling Erythropoietin products.

DNAPrint Genomics is already working with Dr. Sytkowski and BIDMC to develop a new, more potent and longer acting form of the drug Erythropoietin (EPO) for the treatment of anemia. Under the terms of that agreement, BIDMC has granted the Company an exclusive license to United States and foreign patents related to certain forms of EPO, including PT-401.

EPO is a glycoprotein naturally made by the body to stimulate red blood cell production. The currently marketed forms are manufactured using recombinant DNA technology and are used to treat anemia or low red blood cell count. DNAPrint Pharmaceuticals, Inc., a subsidiary of DNAPrint Genomics, has the right to develop, use, market and sell products derived from the licensed patents.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a major patient care, teaching and research affiliate of Harvard Medical School, and ranks fourth in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, Visit www.bidmc.harvard.edu.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

 Company Contact: Richard Gabriel CEO and President 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848  

SOURCE: DNAPrint Genomics, Inc.

Source: MARKET WIRE

More News in this Category